310P - Oral leukoplakia in women treated with long-term pegylated liposomal doxorubicin

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer agents
Complications/Toxicities of Treatment
Gynaecological Malignancies
Presenter Hidetaka Nomura
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors H. Nomura, M. Nagashima, M. Matoda, S. Okamoto, H. Kanao, K. Kato, K. Omatsu, Y. Sugiyama, K. Utsugi, N. Takeshima
  • Gynecology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP



Pegylated liposomal doxorubicin (PLD) is approved for the treatment of Kaposi’s sarcoma and recurrent ovarian cancer. Some case series have recently reported that long-term treatment with PLD may cause squamous cell carcinoma of the tongue and oral cavity. However, the natural history of these carcinomas is not fully understood. This study aimed to investigate changes in the oral cavity of patients treated with PLD.


After approval by the institutional review board, we searched medical records and found 16 patients with recurrent ovarian cancer who were administered more than 10 cycles of PLD. In our hospital, every patient treated with PLD has an oral examination each time before the administration of PLD for the purpose of detecting stomatitis. We retrospectively reviewed the medical records of those 16 patients.


The median number of cycles of PLD was 13, and the median dose of PLD was 625 mg/m2. Leukoplakia, which is known as a precancerous lesion of the oral cavity, was diagnosed in six patients. Squamous cell carcinoma of the oral cavity was not observed in the patients included in our study. Among the six patients, the median number of cycles of diagnosis of leukoplakia was 16 (range, 9–19) and the median dose of PLD was 745 mg/m2. A strong tendency between the dose of PLD and leukoplakia was indicated using the Pearson correlation coefficient (0.84).


Patients with leukoplakia of the oral cavity were found among those treated with long-term PLD administration. The proportion of leukoplakia increased in a dose-dependent manner. Squamous cell carcinoma of the oral cavity induced by PLD may be shown to arise from leukoplakia. Therefore, a periodic oral check is recommended, especially for patients who are administered more than 10 cycles of PLD, to avoid squamous cell carcinoma of the oral cavity.

Clinical trial indentification


Legal entity responsible for the study

Hidetaka Nomura




All authors have declared no conflicts of interest.